Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic

AIDS

Volumn 21, Issue 3, 2007, Pages 317-324

  Martinez Steele, Euridice ^b   Awasana, Akum Aveika ^a   Corrah, Tumani ^a   Sabally, Saihou ^a   Van Der Sande, Marianne ^a   Jaye, Assan ^a   Togun, Toyin ^a   Sarge Njie, Ramu ^a   McConkey, Samuel J ^a   Whittle, Hilton ^a   Schim Van Der Loeff, Maarten F ^a,c  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Africa; AIDS; CD4; HIV 1; HIV 2; Mortality; The Gambia; West Africa

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AFRICA; ARTICLE; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GAMBIA; GROUPS BY AGE; HEALTH CARE FACILITY; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; STRAIN DIFFERENCE; SURVIVAL; TIME OF DEATH; WASTING SYNDROME; WORLD HEALTH ORGANIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; FEMALE; FOLLOW-UP STUDIES; GAMBIA; HIV WASTING SYNDROME; HIV-1; HIV-2; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUBERCULOSIS, PULMONARY;

EID: 33846572410     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328011d7ab     Document Type: Article

References (36)

1. Schim van der Loeff MF, Aaby P. Towards a better understanding of the epidemiology of HIV-2. AIDS 1999; 13 (uppl A):S69-84.
2. Schim van der Loeff MF, Jaffar S, Aveika AA, Sabally S, Corrah T, Harding E, et al. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS 2002; 16:1775-1783.
3. Hansmann A, Schim van der Loeff M, Kaye S, Aveika AA, Sarge-Njie R, O'Donovan D, et al. Baseline plasma viral load and CD4 percentage predict survival in HIV-1 and HIV-2-infected women in a community-based cohort in The Gambia. J Acquir Immune Defic Syndr 2005; 38:335-341.
4. Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, N'Gbichi JM, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993; 7:1569-1579.
5. Ariyoshi K, Schim van der Loeff M, Cook P, Whitby D, Corrah T, Jaffar S, et al. Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpes virus 8. J Human Virol 1998; 1:193-199.
6. Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA. Review of human inmmunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis 2003; 36:652-662.
7. Chequer P, Hearst N, Hudes ES, Castilho E, Rutherford G, Loures L, et al. Determinants of survival in adult Brazilian AIDS patients, 1982-1989. AIDS 1992; 6:483-487.
8. Kitayaporn D, Tansuphaswadikul S, Lohsomboon P, Pannachet K, Kaewkungwal J, Limpakarnjanarat K, et al. Survival of AIDS patients in the emerging epidemic in Bangkok, Thailand. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:77-82.
9. Whittle H, Egboga A, Todd J, Corrah T, Wilkins A, Demba E, et al. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection. AIDS 1992; 6:685-689.
10. Whittle H, Morris J, Todd J, Corrah T, Sabally S, Bangali J, et al. HIV-2-infected patients survive longer than HIV-1-infected patients. AIDS 1994; 8:1617-1620.
11. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth J. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 2002; 16:597-603.
12. French N, Mujugira A, Nakiyingi J, Mulder D, Janoff EN, Gilks CF. Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease. J Acquir Immune Defic Syndr 1999; 22:509-516.
13. Salinari RK, Filippo C, Claudio C. Preliminary survival analysis of AIDS data from Goma, Zaire. Trop Doct 1990; 20:169-170.
14. Jaffar S, Grant AD, Whitworth J, Smith PG, Whittle H. The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull WHO 2004; 82: 462-469.
15. Naucler A, Albino P, Andersson S, Paolo da Silva A, Linder H, Andreasson PA, et al. Clinical and immunological follow-up of previously hospitalized HIV-2 seropositive patients in Bissau, Guinea-Bissau. Scand J Infect Dis 1992; 24:725-731.
16. Mocroft A, Johnson MA, Phillips AN. Factors affecting survival in patients with the acquired immunodeficiency syndrome. AIDS 1996; 10:1057-1065.
17. Bakari M, Urassa W, Pallangyo K, Swai A, Mhalu F, Biberfeld G, Sandström E. The natural course of disease following HIV-1 infection in Dar es Salaam, Tanzania: a study among hotel workers relating clinical events to CD4+ T-lymphocyte counts. Scand J Infect Dis 2004; 36:466-473.
18. Matheron S, Mendoza-Sassi G, Simon F, Olivares R, Coulaud JP, Brun-Vezinet F. HIV-1 and HIV-2 AIDS in African patients living in Paris [letter]. AIDS 1997; 11:934-936.
19. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 2:634-656.
20. World Health Organisation. Acquired Immune Deficiency Syndrome (AIDS) Interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemiol Rec 1990; 65:221-224.
21. Van der Sande MAB, Schim van der Loeff MF, Aveika AA, Sabally A, Togun T, Sarge-Njie R, et al. Body mass index at time of HIV diagnosis. A strong and independent predictor of survival. J Acquir Immune Defic Syndr 2004; 37:1288-1294.
22. World Health Organisation. WHO case definitions for AIDS surveillance in adults and adolescents. Wkly Epidemiol Rec 1994; 69:273-275.
23. De Cock KM, Selik RM, Soro B, Gayle H, Colebunders RL. AIDS surveillance in Africa: a reappraisal of case definitions. BMJ 1991; 303:1185-1188.
24. Morgan D, Malamba SS, Orem J, Mayanja B, Okongo M, Whitworth JA. Survival by AIDS defining condition in rural Uganda. Sex Transm Infect 2000; 76:193-197.
25. Ndour M, Sow PS, Coll-Seck AM, Badiane S, Ndour CT, Diakhate N, et al. AIDS caused by HIV1 and HIV2 infection: are there clinical differences? Results of AIDS surveillance 1986-97 at Fann Hospital in Dakar, Senegal. Trop Med Int Health 2000; 5:687-691.
26. Gallo RC. HIV-1, HHV-8, and Kaposi's sarcoma. J Hum Virol 1998; 1:185-186.
27. Le Guenno BM, Barabe P, Griffet PA, Guiraud M, Morcillo RJ, Peghini ME, et al. HIV-2 and HIV-1 AIDS cases in Senegal: clinical patterns and immunological perturbations. J Acquir Immune Defic Syndr 1991; 4:421-427.
28. Norrgren H, Da Silva ZJ, Andersson S, Biague AJ, Dias F, Biberfeld G, et al. Clinical features, immunological changes and mortality in a cohort of HIV-2-infected individuals in Bissau, Guinea-Bissau. Scand J Infect Dis 1998; 30:323-329.
29. Matheron S, Pueyo S, Damond F, Simon F, Lepretre A, Campa P, et al. Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort. AIDS 2003; 17:2593-2601.
30. Moore RD, Chaissson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996; 124:633-642.
31. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, et al. The prognostic value of cellular and serological markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322:166-172.
32. Berry N, Jaffar S, Schim van der Loeff M, Ariyoshi K, Harding E, N'Gom PT, et al. Low level viremia and high CD4% predict normal survival in a cohort of HIV type-2-infected villagers. AIDS Res Hum Retroviruses 2002; 18:1167-1173.
33. Cox S, Aperia K, Albert J, Wahren B. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiretroviral drugs and drug combinations. AIDS Res Hum Retroviruses 1994; 12:1725-1728.
34. Witvrouw M, Pannecouque C, Laethem KV, Desmyter J, De Clercq E, Vandamme AM. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 1999; 13:1477-1483.
35. Kanki PJ, De Cock KM. Epidemiology and natural history of HIV-2. AIDS 1994; 8 (suppl 1):S85-S93.
36. Schim van der Loeff MF, Aveika Awasana A, Sarge-Njie R, van der Sande M, Jaye A, Sabally S, et al. Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Intl J Epidemiol 2006; Advance access published on March 16, 2006; doi: doi:10.1093/ije/dyl037.